The Delhi High Court has ordered the appointment of a forensic auditor to investigate the alleged dissipation of the shareholding of Fortis Healthcare’s erstwhile promoters, Malvinder Mohan Singh and Shivinder Mohan Singh, and the subsequent change in control of the hospital chain.

The order was passed on August 31, 2026, in the long-running matter Daiichi Sankyo Company, Limited vs. Malvinder Mohan Singh & Ors., arising from execution applications filed in 2022 and 2025.

The forensic audit will examine the factual circumstances surrounding the dilution and transfer of the Singh Brothers’ shareholding, the change in Fortis’ control, and the role of various stakeholders, including banks, financial institutions and the erstwhile promoters.

Fortis Healthcare clarified that the order does not impose any liability, penalty or fine on the company. It said Fortis was neither a party to the original dispute nor a judgment debtor in the execution proceedings.

The company described the forensic audit as “purely investigative in nature”, stressing that the direction does not by itself determine or fasten any liability on Fortis.

Fortis said it is reviewing the order with its legal advisers and will determine the appropriate course of action in accordance with applicable law.

The latest development is linked to the long-standing dispute between Daiichi Sankyo and the Singh Brothers following Daiichi Sankyo’s 2008 acquisition of Ranbaxy Laboratories from the promoters.